Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Biogen CEO to leave as Alzheimer's drug struggles
12:32pm, Tuesday, 03'rd May 2022
Biogen said on Tuesday its Chief Executive Michel Vounatsos will step down, with the drugmaker adding it would scale down its sales infrastructure for the controversial Alzheimer's drug Aduhelm.
Biogen Inc. (BIIB) Q1 Earnings Miss Estimates
12:25pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of -17.91% and 1.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig
12:02pm, Tuesday, 03'rd May 2022
Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.
Read Why Biogen Sares Are Trading Higher After Q1 Earnings
10:39am, Tuesday, 03'rd May 2022
Biogen Inc (NASDAQ: BIIB) posted Q1 sales of 2.53 billion, beating the consensus of $2.49 billion, down 6% Y/Y. Multiple sclerosis (MS) revenue, including royalties on sales of Ocrevus, of $1.79 bil
Biogen CEO Steps Down After Quarterly Earnings Miss
10:16am, Tuesday, 03'rd May 2022
Biogen Inc (NASDAQ:BIIB) stepped into the earnings confessional today to post first-quarter earnings of $3.62 per share -- lower than the $4.38 per share analysts anticipated -- due to Alzheimer's
Biogen CEO Stepping Down After Struggles With Alzheimer's Drug Aduhelm
10:08am, Tuesday, 03'rd May 2022
The company said it will substantially eliminate the sales infrastructure related to Aduhelm, which is intended to provide savings of $1 billion annually when combined with other cost reductions.
Biogen Inc. (BIIB) Q1 Earnings Miss Estimates
09:47am, Tuesday, 03'rd May 2022
Biogen Inc. (BIIB) delivered earnings and revenue surprises of -17.91% and 1.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen CEO Michel Vounatsos to step down following troubled Alzheimer's drug launch
09:31am, Tuesday, 03'rd May 2022
CNBC's Meg Tirrell joins 'Squawk Box' to report that Biogen CEO Michel Vounatsos will step down amid the company's troubled launch of its historic Alzheimer's drug Aduhelm.
Biogen CEO Michel Vounatsos to step down
07:48am, Tuesday, 03'rd May 2022
Biogen Inc. BIIB, -0.06% said Tuesday that it is conducting a search to replace CEO Michel Vounatsos, who will stay in his role unless a successor is named. The announcement was made in the company's
Biogen'a Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug
07:35am, Tuesday, 03'rd May 2022
Shares of Biogen Inc. BIIB, -0.06% fell 2.3% in premarket trading on Tuesday after the company missed Wall Street's expectations for revenue and earnings for the first quarter of 2022. Biogen had net
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
07:55pm, Monday, 02'nd May 2022 Zacks Investment Research
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
05:18pm, Monday, 02'nd May 2022
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen
10:22am, Monday, 02'nd May 2022 Zacks Investment Research
Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.
Sage, Biogen start 'rolling submission' to FDA for depression drug
07:52am, Monday, 02'nd May 2022
Sage Therapeutics Inc. SAGE, -2.78% and Biogen Inc. BIIB, -1.41% said Monday that they started a rolling submission to the Food and Drug Administration for zuranolone, a treatment they are developing
Pfizer (PFE) to Report Q1 Earnings: What's in the Cards?
03:56pm, Friday, 29'th Apr 2022 Zacks Investment Research
Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the first quarter.
